Budesonide for Acute radiation proctitis|Prostate cancer

Inclusion criteria

• {"criterion_text":"- Age and Sex: - Male patients (i.e., sex assigned at birth inclusive all gender identities) aged at least 18 years, at the time of signing the informed consent\n- Type of Participant and Disease Characteristics: - Diagnosis of prostate carcinoma (primary or biochemical recurrence); - Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≤2 or Karnofsky performance status 70% (refer to Table 12. Karnofsky performance status); - Local radiotherapy by external beam radiation planned; - Conventional external beam RT with 60-80 Gy complete dose in 20-40 fractions over 4-8 weeks\n- Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≤2 or Karnofsky performance status 70%\n- Local radiotherapy by external beam radiation planned.\n- Conventional external beam RT with 60-80 Gy complete dose in 20-40 fractions over 4-8 weeks.\n- Signed informed consent as described in Section 10.1.3 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n- CTCAE grading for proctitis and diarrhea ≥ grade 1 for at least 3 days.\n- Sufficient compliance in ePRO as assessed during screening period (defined as at least 3 ePRO entries per week)."}

Exclusion criteria

• {"criterion_text":"- Treatment by brachytherapy\n- Concomitant medication with systemic and/or topical corticosteroids, other immunosuppressants, or medication that affect peristalsis and/or the intestinal mucosa (e.g., antibiotics, loperamide, opioids, laxatives)\n- Participation in another clinical study and having received an IMP within 30 days prior to Visit 0 (Screening visit) or within 5 half-lives of IMP, whichever is longer\n- Crohn’s disease, indeterminate colitis, ischemic colitis, ulcerative colitis, microscopic colitis (i.e., collagenous colitis or lymphocytic colitis)\n- Grade III internal hemorrhoids\n- Perianal dermatitis\n- Significant bacterial, amoebic, fungal, or viral infections of the gut\n- History of any RT in the area of the pelvis and/or the lower abdomen\n- Active colorectal cancer or a history of colorectal cancer\n- Active malignancy other than prostate cancer or treatment with antineoplastic drugs during the last 5 years. Patients with a history of cancer (other than prostate cancer) and at least 5 years of uneventful follow-up and no signs of recurrence may be eligible\n- Phenylketonuria\n- Severe renal impairment (GFR ≤ 29 ml /min /1.73 m2 at Baseline) calculated by CKD EPI 2009\n- Known intolerance/hypersensitivity/resistance to the IMP and excipients or drugs of similar chemical structure or pharmacological profile.\n- Known to be or suspected of being unable to comply with the clinical study protocol (e.g., no permanent address, history of drug abuse, known to be non-compliant, or presenting an unstable psychiatric history).\n- Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible impact of the clinical study.\n- Patients in custody by juridical or official order or patients who are institutionalized because of legal or regulatory order.\n- Patient, who is a member of the staff of the study center, staff of the sponsor or clinical research organization, the investigator him-/herself or close relatives of the investigator.\n- Patients with morning serum cortisol serum < 4 µg/dL\n- Active infections, clinically apparent uncontrolled hypertension, diabetes mellitus (including familiar predisposition), active peptic ulcer, osteoporosis, glaucoma, cataract, or other conditions where corticoids may have side effects if careful medical monitoring is not ensured in the opinion of the investigator\n- Immunocompromised patients (e.g., due to human immunodeficiency virus infection) (respective diagnosis in medical history).\n- Diagnosis of chickenpox, herpes zoster, or measles within 3 months prior to Baseline\n- Portal hypertension or liver cirrhosis\n- Abnormal hepatic parameters (ALT, AST or AP > 2.5 x upper limit of normal) or known significant functional disorder of the liver\n- Having received live vaccine(s) within the last 14 days prior to Baseline"}

Primary endpoints

• {"endpoint_text":"- Time to first improvement in CTCAE grading for proctitis is defined as the number of days from Baseline to the first occurrence of a lower CTCAE grading compared to Baseline, sustained for at least three consecutive days","definition_or_measurement_approach":"Time to first improvement in CTCAE grading for proctitis is defined as the number of days from Baseline to the first occurrence of a lower CTCAE grading compared to Baseline, sustained for at least three consecutive days"}

Secondary endpoints

• {"endpoint_text":"- Percentage of participants with reduction in CTCAE grading for proctitis by one and by two score point(s) from Baseline to Visit 2 and Baseline to Visit 4\n- Time to first improvement in CTCAE grading for diarrhea after Baseline, where improvement is defined as a lower CTCAE grading compared to Baseline for at least three consecutive days\n- Percentage of participants with reduction in CTCAE grading for diarrhea by one and by two score point(s) from Baseline to Visit 2 and Baseline to Visit 4\n- Time to first improvement in CTCAE grading for rectal pain after Baseline, where improvement is defined as a lower CTCAE grading compared to Baseline for at least three consecutive days\n- Percentage of participants with reduction in CTCAE grading for rectal pain by one and by two score point(s) from Baseline to Visit 2 and Baseline to Visit 4\n- Time to first improvement in each CTCAE grading for further terms of the lower GI composite (fecal incontinence, lower GI hemorrhage, GI pain and other GI-disorder), where improvement is defined as a lower CTCAE grading compared to Baseline for at least three consecutive days\n- Percentage of participants with reduction in each CTCAE gradings for further terms of the lower GI composite (fecal incontinence, lower GI hemorrhage, GI pain and other GI-disorder) by one and by two score point(s) from Baseline to Visit 2 and Baseline to Visit 4\n- Course and change from Baseline in the SHS-GI sum score and sub-scores at Visit 2, 4, and 5\n- Course and change from Baseline in the PGI-S at Visit 2, 4, and 5\n- PGI-C at Visit 2 and 4\n- Course and change from Baseline in the EPIC Bowel Domain Score at Visit 2, 4, and 5\n- Therapeutic success at Visit 4, defined as complete relief or marked improvement of symptoms according to the PGA\n- Therapeutic benefit at Visit 4, defined as at least a slight improvement according to the PGA\n- Assessment of efficacy by investigator and participant at Visit 4\n- Percentage of participants who remained symptom-free for at least ten consecutive days at Visit 4\n- Percentage of participants who used rescue medication at Visit 4.\n- Duration of rescue medication use at Visit 4\n- Assessment of tolerability by investigator and participant at Visit 4\n- Average daily bowel movement frequency within the treatment period\n- Percentage of days within the treatment period with pain during bowel movements\n- Percentage of days within the treatment period with mild pain during bowel movements\n- Percentage of days within the treatment period with moderate pain during bowel movements\n- Percentage of days within the treatment period with severe pain during bowel movements\n- Percentage of days within the treatment period with bloody stool\n- Percentage of days within the treatment period with mucous stool\n- Percentage of days within the treatment period with uncontrolled bowel movements\n- Percentage of days within the treatment period during which no pads were used due to uncontrolled bowel movement\n- Percentage of days within the treatment period during which pads were used sometimes due to uncontrolled bowl movement\n- Percentage of days within the treatment period during which pads were used most of the time due to uncontrolled bowl movement\n- Percentage of days within the treatment period during which symptoms interfered with daily life\n- Percentage of days within the treatment period during which symptoms interfered with daily functioning to the extent that self-care was impossible\n- Percentage of days within the treatment period during which medical intervention was required due to symptoms","definition_or_measurement_approach":"See endpoint text for definitions/measurement approaches; where provided the CTCAE-based time-to-improvement endpoints are defined as a lower CTCAE grading compared to Baseline sustained for at least three consecutive days; other endpoints are percentage or change-from-baseline assessments at specified visits (Visit 2, Visit 4, Visit 5) using instruments named (SHS-GI, PGI-S, PGI-C, EPIC Bowel Domain Score, PGA) as specified in the protocol."}

Methods

• L2_Other subject information and material_Flyer (patient-facing recruitment flyer document listed in CTIS document set)
• L2_Other subject information and material_PatientCard (patient-facing card listed in CTIS document set)

Austria

Earliest CTIS Part Ii Submission Date

05-03-2026

Latest Decision Or Authorization Date

22-03-2026

Processing Time Days

17

Number Of Sites

4

Number Of Participants

160

Germany

Earliest CTIS Part Ii Submission Date

06-02-2026

Latest Decision Or Authorization Date

06-03-2026

Processing Time Days

28

Number Of Sites

2

Number Of Participants

160

Primary sponsor

Full Name

Dr. Falk Pharma GmbH

Organisation Type

Pharmaceutical company

Country Of Registered Address

Germany

Contract research organisations

Name

Astrum CRO Germany GmbH

Responsibilities

codes:1,10,11,12,2,5,6

Third parties

• {"country":"Germany","full_name":"NextPharma GmbH","duties_or_roles":"code:14","organisation_type":"Pharmaceutical company"}
• {"country":"Germany","full_name":"Astrum CRO Germany GmbH","duties_or_roles":"codes:1,10,11,12,2,5,6","organisation_type":"Pharmaceutical company"}
• {"country":"Germany","full_name":"Labor Dr. Spranger","duties_or_roles":"code:4","organisation_type":"Laboratory/Research/Testing facility"}
• {"country":"Germany","full_name":"AB Cube Germany GmbH","duties_or_roles":"code:7","organisation_type":"Non-Pharmaceutical company"}